A practical reference on REV-ERB: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-08 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
The American military uses a B-1 long-range bomber to strike IRGC targets in Iran for the first time since fighting with Iran resumed 12 days prior. The US House approves a symbolic legislation instructing Trump to cease US military action against Iran, but the Senate backs Trump. Trump indicates he is nearing a decision to restart major combat operations in Iran, potentially involving larger strikes than during Operation Epic Fury. He suggests that while the Iranians "want to negotiate," they are not yet prepared to reach an agreement, stating, "They haven't received enough pain yet." The New York Times reports that Iran rejected a US cease-fire plan provided by Iraqi Prime Minister Ali al-Zaidi, stating that their government was not interested in a temporary agreement that left the subject of control over the Strait of Hormuz unresolved. Several people are reported to have died from a Legionnaires outbreak in New York City, while several dozen have been infected over the past month. United States Trade Representative Jamieson Greer imposes tariffs of 10% or 12.5% on most imports from 60 major trading partners, including China, the United Kingdom and the European Union, citing their failure to adequately restrict imports produced using forced labour. The countries and territories affected account for 99.4% of US imports. Vance Boelter is sentenced to two life terms without parole for killing Minnesota state representative Melissa Hortman and her husband and wounding state senator John Hoffman and his wife in June 2025.
223Fr is the result of the alpha decay of 227Ac and can be found in trace amounts in uranium minerals. In a given sample of uranium, there is estimated to be only one francium atom for every 1 × 1018 uranium atoms. Only about 1 ounce (28 g) of francium is present naturally in the earth's crust.
The biguanide class of antidiabetic medications, which also includes the withdrawn agents phenformin and buformin, originates from research on Goat's rue (Galega officinalis) also known as Galega, French lilac, Italian fitch, Spanish sainfoin, Pestilenzkraut, or Professor-weed. (The plant should not be confused with plants in the genus Tephrosia which are highly toxic and sometimes also called Goat's rue.) Galega officinalis has been used in folk medicine for several centuries. G. officinalis itself does not contain biguanide medications which are chemically synthesized compounds composed of two guanidine molecules joined together and designed to be less toxic than the plant-derived parent compound galegine (isoamylene guanidine). Metformin was first described in the scientific literature in 1922, by Emil Werner and James Bell, as a product in the synthesis of N,N-dimethylguanidine. In 1929, Slotta and Tschesche discovered its sugar-lowering action in rabbits, finding it the most potent biguanide analog they studied. This result was ignored, as other guanidine analogs such as the synthalins, took over and were themselves soon overshadowed by insulin. Interest in metformin resumed at the end of the 1940s. In 1950, metformin, unlike some other similar compounds, was found not to decrease blood pressure and heart rate in animals. That year, Filipino physician Eusebio Y. Garcia used metformin (he named it Fluamine) to treat influenza; he noted the medication "lowered the blood sugar to minimum physiological limit" and was not toxic.
== Mechanism == EAAT1 functions in vivo as a homotrimer. EAAT1 mediates the transport of glutamic and aspartic acid with the cotransport of three Na+ and one H+ cations and counter transport of one K+ cation. This co-transport coupling (or symport) allows the transport of glutamate into cells against a concentration gradient.
== Methodology == To ensure consistency and repeatability, the methods use in the chemical analysis of water samples are often agreed and published at a national or state level. By convention these are often referred to as "Blue book". Certain analyses are performed in-field (e.g. pH, specific conductance) while others involve sampling and laboratory testing. The methods defined in the relevant standards can be broadly classified as:
Sources: en.wikipedia.org
On inhalation and exhalation air moves through the airways in the same direction, thus creating a unidirectional airflow through the lungs. A similar system is found in birds, monitor lizards and iguanas. Most reptiles lack a secondary palate, meaning that they must hold their breath while swallowing. Crocodilians have evolved a bony secondary palate that allows them to continue breathing while remaining submerged (and protect their brains against damage by struggling prey). Skinks (family Scincidae) also have evolved a bony secondary palate, to varying degrees. Snakes took a different approach and extended their trachea instead. Their tracheal extension sticks out like a fleshy straw, and allows these animals to swallow large prey without suffering from asphyxiation.
Globally, about 2 percent of soybean meal is used for soy flour and other products for human consumption. Soy flour is used to make some soy milks and textured vegetable protein products, and is marketed as full-fat, low-fat, defatted, and lecithinated types.
A Broadway production named Shining City was Platt's Broadway debut in 2006. The play was set in Dublin, and Platt's role was the tortured protagonist, John. Shining City's director said, "There is one word to describe Oliver. It's 'humanity.' He's got that everyman quality. He's a contradictory human being with flaws and strengths. And he's loveable. He can simultaneously make you laugh and break your heart. Oliver has brought to the role of John what I expected and more: tremendous inventiveness and sensitivity." Platt visited Dublin to prepare for the role and ensure his performance was authentic. He was nominated for a Tony Award for "Best Performance by a Leading Actor in a Play". In 2007, Platt played the part of Yankees owner George Steinbrenner in the ESPN mini-series The Bronx Is Burning. Platt signed onto the project after John Turturro was confirmed as Billy Martin, because "This thing lives or dies by that portrayal ... I think it's great casting. God knows he has the intensity." Platt starred in the pilot episode of The Thick of It, a remake of the British show of the same name in 2007. The series was not picked up by ABC. Platt starred as Nathan Detroit, alongside Lauren Graham as Miss Adelaide, in the Broadway revival of Guys and Dolls which began performances at the Nederlander Theatre on February 3, 2009, and officially opened on March 1, 2009. The production closed on June 14, 2009, after 113 performances. Platt starred as White House Chief of Staff Carl Anheuser in Roland Emmerich's 2012, a disaster film released November 13, 2009.
"Top-up" transfusions, to replace losses due to investigational losses and correction of anemia. Exchange (or partial exchange) transfusions are done for removal of bilirubin, removal of antibodies and replacement of red cells (e.g., for anemia secondary to thalassemias and other hemoglobinopathies or fetal erythroblastosis).
Sources: en.wikipedia.org
== Clinical significance == Mutations in the 38 human genes for the cytoplasmic and mitochondrial enzymes have been associated with a wide range of illnesses, with 56+ different diseases given OMIM codes. The majority of reported diseases (46/56) were autosomal recessive. Nearly every reported aminoacyl-tRNA synthetase gene has been associated with at least one disease caused by mutations (with the notable exception of TARS3). Mutations in the mitochondrial enzyme have been associated with a number of genetic disorders including Leigh syndrome, West syndrome and CAGSSS (cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss and skeletal dysplasia syndrome).
Monoclonal+antibodies at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Antibodypedia, open-access virtual repository publishing data and commentary on any antibodies available to the scientific community. Antibody Purification Handbook Archived 5 December 2008 at the Wayback Machine
== Therapeutic potential == In a test of pharmacologic asprosin depletion in animals, preliminary results raised the possibility of its use, therapeutically, in treating type 2 diabetes and obesity. For instance, Chopra and coworkers observed that when monoclonal antibodies targeting asprosin were injected into diabetic mice, blood glucose and insulin levels improved.
==== Involvement of Mexican cartels in the Russo-Ukrainian War ==== In July 2025, the Mexican Intelligence in collaboration with Ukrainian security forces, revealed that in the Russian invasion of Ukraine Colombian and Mexican mercenaries were sent in the war-zone in the International Legion by the drug cartels to gain war tactics and especially knowledge on the use of drones FPV for battles with the security forces and rival cartels in Mexico. In August 2025, it was revealed that the Jalisco New Generation Cartel (CJNG) created a specific paramilitary unit, of at least 10 members, for the use of drones FPV using the tactics learned in the War in Ukraine.
=== Joint definition by IUPAP and IUPAC === The existence of two distinct units with the same name was confusing, and the difference (about 1.000282 in relative terms) was large enough to affect high-precision measurements. Moreover, it was discovered that the isotopes of oxygen had different natural abundances in water and in air. In April 1957 Alfred O. C. Nier suggested to Josef Mattauch that carbon-12 be adopted as the mass scale because of carbon's use as a secondary standard in mass spectrometry. Also, carbon-12 implied acceptable relative changes in the atomic weight scale, i.e., 42 parts-per-million (ppm) compared to 275 ppm for oxygen-16, which would not be acceptable to chemists. Following the approval of the International Union of Pure and Applied Physics (IUPAP) General Assembly at Ottawa, Canada, in 1960 and the International Union of Pure and Applied Chemistry (IUPAC) General Assembly at Montreal, Canada, in 1961, the atomic weights were officially given on the carbon-12 scale for the first time. The new unit was named the "unified atomic mass unit" and given a new symbol "u", to replace the old "amu" that had been used for the oxygen-based unit. However, the old symbol "amu" has sometimes been used after 1961 to refer to the new unit, particularly in lay and preparatory contexts. With this new definition, the standard atomic weight of carbon is about 12.011 Da and that of oxygen is about 15.999 Da. These values, generally used in chemistry, are based on averages of many samples from Earth's crust, its atmosphere, and organic materials.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.